Clinical Trial Update: A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating abiraterone acetate in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Sponsor: Cougar Biotechnology, Inc. | Conditions: Prostate Neoplasms, Prostate Cancer | Phase 1 | Status: COMPLETED